Metabolic concerns associated with antiepileptic medications
The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
Platinum drugs comprise one of the main classes of chemotherapy drugs that can induce remissions in various solid tumors. Although tumors often regress on treatment withcis-diamminedichloroplatinum II (cisplatin) orcis-diammine-1,1-cyclobutane dicarboxylate platinum II (carboplatin), they usually relapse as a drug-resistant tumor. Most mechanisms of platinum resistance could be overcome by increasing the amount of drug that is accumulated by tumor cells. Amphotericin B (Amph B) is efficient at increasing platinum drug uptake, but because of nephrotoxicity associated with extended usage, and the potential for synergistic nephrotoxicity when used with platinum drugs, Amph B has not been used clinically for this purpose. A liposomal preparation of Amph B (LipoAmph B), which is substantially less nephrotoxic, was studied for its ability to enhance platinum-drug toxicity to a human oral squamous cell carcinoma line, HN-5a, and its carboplatin-resistant variant, 5a/carbo-15a, in which cisplatin accumulation was reduced by approximately 40%. Amph B at 10 μg/ml enhanced cisplatin accumulation by approximately 100% in both cell lines, enhancing cytotoxicity of the drugs by 35 to 60%, and completely reversed resistance to both cisplatin and carboplatin. LipoAmph B in the presence of phospholipase A2-II (PLA2-II) was able to enhance cisplatin and carboplatin cytotoxicity as effectively as free Amph B in both cell lines. At optimal concentrations, LipoAmph B plus PLA2-II enhanced drug uptake sufficiently to abolish resistance in the platinum-resistant line. Because PLA2-II is elevated in some tumor microenvironments and in plasma of ill patients, LipoAmph B has potential clinical usefulness as a modulator of platinum-drug efficacy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sugai, K. (2004) · Epilepsia · doi:10.1111/j.0013-9580.2004.458005.x · Cited by 39
Cited by
The Ketogenic diet: from molecular mechanisms to clinical effects
(2006) · Epilepsy Research · doi:10.1016/j.eplepsyres.2005.10.003 · Cited by 213
Drug-induced kidney stones and crystalline nephropathy: pathophysiology, prevention and treatment
Daudon, M., Frochot, V., Bazin, D., & Jungers, P. (2018) · Drugs · doi:10.1007/s40265-017-0853-7 · Cited by 191
Does Treatment With Duloxetine for Neuropathic Pain Impact Glycemic Control?
Hardy, T., Sachson, R., Shen, S., Armbruster, M., & Boulton, A. J. M. (2007) · Diabetes Care · doi:10.2337/dc06-0947 · Cited by 79
Metadata
- Authors
- Sheth, R. D.
- Venue
- Neurology
- Published
- 2004-11-23
- Volume
- 63
- Issue
- 10_suppl_4
- Pages
- S24-9
- ISSN
- 0028-3878 (ISSN-L)
- 1526-632X
- OpenAlex
- W2016821109
- Cited by
- 119
- References
- 1
- FWCI
- 8.08
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Metabolic concerns associated with antiepileptic medications. https://app.cochat.ai/papers/10.1212/wnl.63.10_suppl_4.s24
- The paper
- Sheth, R. D. (2004). Metabolic concerns associated with antiepileptic medications. Neurology. https://doi.org/10.1212/wnl.63.10_suppl_4.s24
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.